for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cytosorbents Corp

CTSO.OQ

Latest Trade

8.58USD

Change

-0.24(-2.72%)

Volume

75,612

Today's Range

8.54

 - 

8.88

52 Week Range

3.61

 - 

11.74

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.82
Open
8.79
Volume
75,612
3M AVG Volume
5.70
Today's High
8.88
Today's Low
8.54
52 Week High
11.74
52 Week Low
3.61
Shares Out (MIL)
43.18
Market Cap (MIL)
380.81
Forward P/E
-38.36
Dividend (Yield %)
--

Next Event

Cytosorbents Corp Annual Shareholders Meeting

Latest Developments

More

Cytosorbents- Prelim 2020 Unaudited Total Revenue Was About $40.8 Mln Vs $24.9 Mln In 2019

Cytosorbents Reports Preliminary Q4 And Full Year 2020 Revenue

CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cytosorbents Corp

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.

Industry

Medical Equipment & Supplies

Contact Info

7 Deerpark Dr Ste K

MONMOUTH JUNCTION, NJ

08852-1977

United States

http://cytosorbents.com/

Executive Leadership

Al W. Kraus

Independent Non-Executive Chairman of the Board

Phillip P. Chan

President, Chief Executive Officer, Director

Kathleen P. Bloch

Chief Financial Officer

Vincent J. Capponi

Chief Operating Officer

Michael G. Bator

Independent Director

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.320

2018

-0.560

2019

-0.600

2020(E)

-0.230
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.44
Price To Book (MRQ)
4.75
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
18.89
LT Debt To Equity (MRQ)
7.47
Return on Investment (TTM)
-20.90
Return on Equity (TTM)
-16.71

Latest News

Latest News

BRIEF-Cytosorb Adds Bilirubin And Myoglobin Reduction To Eu Approved Indications For Use

* CYTOSORB® ADDS BILIRUBIN AND MYOGLOBIN REDUCTION TO EUROPEAN UNION APPROVED INDICATIONS FOR USE

BRIEF-CytoSorbents Reports Qtrly Loss Per Share $0.10

* CYTOSORBENTS REPORTS STRONG FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cytosorbents Enrolls First Patient Into Pivotal U.S. Refresh 2-AKI Trial

* CYTOSORBENTS ENROLLS FIRST PATIENT INTO PIVOTAL U.S. REFRESH 2-AKI TRIAL USING CYTOSORB® DURING COMPLEX CARDIAC SURGERY Source text for Eikon: Further company coverage:

BRIEF-Cytosorbents Refinances Existing Debt With New $15 Mln Debt Facility With Bridge Bank

* CYTOSORBENTS REFINANCES EXISTING DEBT WITH NEW $15 MILLION DEBT FACILITY WITH BRIDGE BANK

BRIEF-Cytosorbents Achieves Record Revenue And Product Sales Growth In 2017

* CYTOSORBENTS ACHIEVES RECORD REVENUE AND PRODUCT SALES GROWTH IN 2017

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

BRIEF-Cytosorbents Sees Q4 2017 Revenue About $4.6 Million

* CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up